In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Advances in gene editing tools like CRISPR‑Cas9 and pre-implantation embryo screening are turning the idea of designer babies ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...